EyePoint Pharmaceuticals
02.04.19
EyePoint Pharmaceuticals Announces US Commercial Launch of YutiqSource: EyePoint Pharmaceuticals
01.28.19
EyePoint Pharmaceuticals Appoints David Guyer, MD, to Board of DirectorsSource: EyePoint Pharmaceuticals
01.03.19
EyePoint Pharmaceuticals to Launch Dexycu and Yutiq in First Quarter of 2019Source: EyePoint Pharmaceuticals
11.27.18
EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company SecretarySource: EyePoint Pharmaceuticals
11.12.18
EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for Dexycu by CMSSource: EyePoint Pharmaceuticals
10.29.18
EyePoint Pharmaceuticals Presents Positive Yutiq 24-month Follow-up Data at AAOSource: EyePoint Pharmaceuticals
10.18.18
EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at the AAO 2018 Annual MeetingSource: EyePoint Pharmaceuticals
10.15.18
EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious UveitisSource: EyePoint Pharmaceuticals
10.01.18
EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised WarrantsSource: EyePoint Pharmaceuticals